Unethical human experimentation in the United States
In 1953, the AEC ran several studies at the University of Iowa on the health effects of radioactive iodine in newborns and pregnant women. In one study, researchers gave pregnant women from of iodine-131, in order to study the women's aborted embryos in an attempt to discover at what stage, and to what extent, radioactive iodine crosses the placental barrier. In another study, they gave 25 newborn babies (who were under 36 hours old and weighed from ) iodine-131, either by oral administration or through an injection, so that they could measure the amount of iodine in their thyroid glands, as iodine would go to that gland.
Iodine
The other iodine radioisotopes have much shorter half-lives, no longer than days. Some of them have medical applications involving the thyroid gland, where the iodine that enters the body is stored and concentrated. Iodine-123 has a half-life of thirteen hours and decays by electron capture to tellurium-123, emitting gamma radiation; it is used in nuclear medicine imaging, including single photon emission computed tomography (SPECT) and X-ray computed tomography (X-Ray CT) scans. Iodine-125 has a half-life of fifty-nine days, decaying by electron capture to tellurium-125 and emitting low-energy gamma radiation; the second-longest-lived iodine radioisotope, it has uses in biological assays, nuclear medicine imaging and in radiation therapy as brachytherapy to treat a number of conditions, including prostate cancer, uveal melanomas, and brain tumours. Finally, iodine-131, with a half-life of eight days, beta decays to an excited state of stable xenon-131 that then converts to the ground state by emitting gamma radiation. It is a common fission product and thus is present in high levels in radioactive fallout. It may then be absorbed through contaminated food, and will also accumulate in the thyroid. As it decays, it may cause damage to the thyroid. The primary risk from exposure to high levels of iodine-131 is the chance occurrence of radiogenic thyroid cancer in later life. Other risks include the possibility of non-cancerous growths and thyroiditis.